RhumbLine Advisers’s Prime Medicine PRME Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $242K | Buy |
97,972
+16,072
| +20% | +$39.7K | ﹤0.01% | 3123 |
|
|
2025
Q1 | $163K | Buy |
81,900
+9,944
| +14% | +$19.8K | ﹤0.01% | 3207 |
|
|
2024
Q4 | $210K | Buy |
71,956
+1,909
| +3% | +$5.57K | ﹤0.01% | 3170 |
|
|
2024
Q3 | $271K | Sell |
70,047
-60
| -0.1% | -$232 | ﹤0.01% | 3077 |
|
|
2024
Q2 | $360K | Buy |
70,107
+17,595
| +34% | +$90.4K | ﹤0.01% | 2890 |
|
|
2024
Q1 | $368K | Buy |
52,512
+1,654
| +3% | +$11.6K | ﹤0.01% | 2852 |
|
|
2023
Q4 | $451K | Sell |
50,858
-101
| -0.2% | -$895 | ﹤0.01% | 2725 |
|
|
2023
Q3 | $486K | Buy |
50,959
+3,896
| +8% | +$37.2K | ﹤0.01% | 2628 |
|
|
2023
Q2 | $689K | Buy |
+47,063
| New | +$689K | ﹤0.01% | 2496 |
|